Latest news with #EliLillyandCompany
Yahoo
21 hours ago
- Health
- Yahoo
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 Participants in the study who started treatment later still saw benefit. However, earlier initiation of Kisunla in study participants significantly reduced the risk of progression to the next stage of the disease compared to those who received Kisunla treatment later.1 These data were shared as a late breaking 2025 Alzheimer's Association International Conference (AAIC) presentation in Toronto. "The TRAILBLAZER-ALZ 2 long-term extension reaffirms that Kisunla delivered sustained clinical benefit that continued to increase over three years and a consistent safety profile," said Mark Mintun, M.D., group vice president, Neuroscience Research & Development, Eli Lilly and Company. "Participants continued to show meaningful outcomes, reinforcing the long-term value of early intervention." The TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original TRAILBLAZER-ALZ 2 trial, evaluating the efficacy and safety of Kisunla in individuals with early symptomatic Alzheimer's disease.1 Participants originally treated with Kisunla either continued treatment or were switched to placebo, while those initially on placebo began Kisunla in a blinded manner. An external comparator group from ADNI was used to assess outcomes against a matched, untreated population. Key preliminary results from the TRAILBLAZER-ALZ 2 LTE study include: Kisunla benefit continued to grow over three years for participants treated in the study compared to those in the matched ADNI group. Kisunla reduced cognitive decline by -0.6 at 18 months and then -1.2 at 36 months on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in patients initially treated with Kisunla in the core study compared to the ADNI group. Earlier initiation of Kisunla reduced the risk of progression to the next stage of disease by 27% on the Clinical Dementia Rating-Global Score (CDR-G) compared to a delayed initiation Kisunla group. More than 75% of participants treated with Kisunla reached amyloid clearance within 76 weeks of starting treatment. After up to 2.5 years of observed data in participants who had completed treatment, amyloid plaque reaccumulation remained slow at a rate of approximately 2.4 CL/year, consistent with prior observations and modeling. No new safety signals were observed in the LTE over the three years, further reinforcing the established safety profile for Kisunla. Amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and with hemorrhage/with hemosiderin deposition are side effects within the class of amyloid targeting therapies that do not usually cause any symptoms, but serious and life-threatening symptoms can occur. ARIA can be fatal. Carriers of one or two copies of the apolipoprotein E ε4 (ApoE4) gene may be at higher risk of developing Alzheimer's disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers. Kisunla can also cause certain types of allergic reactions, some of which may be serious and life-threatening, that typically occur during infusion or within 30 minutes post-infusion.2,3 Headache is another commonly reported side effect. See the Indication and Safety Summary with Warnings below for additional information. About TRAILBLAZER-ALZ 2 Long-Term Extension (LTE) StudyParticipants in the TRAILBLAZER-ALZ 2 (core) study who completed the 76-week placebo-controlled period were eligible to continue into the participant- and investigator-blinded LTE period, lasting an additional 78 weeks. The LTE study included multiple treatment arms: Participants (n=550) initially treated with Kisunla in the main study either continued treatment in the LTE or were switched to placebo after meeting pre-defined amyloid clearance thresholds. These participants were followed in the LTE period to assess long-term Kisunla safety and durability of treatment effects. Participants receiving placebo in the main study switched to Kisunla at the start of the LTE period in a blinded manner to evaluate delayed treatment outcomes. These delayed start participants (n= 657) received Kisunla with the same dosing, administration and stopping criteria as the TRAILBLAZER-ALZ 2 trial. In the study, if the amyloid plaque level was <11 Centiloids on a single positron emission tomography (PET) scan or 11 to <25 Centiloids on 2 consecutive PET scans, the patient was eligible to be switched to placebo. For reference, <24.1 Centiloids on an amyloid PET scan is consistent with a negative visual read. About TRAILBLAZER-ALZ 2 Study and the TRAILBLAZER-ALZ ProgramTRAILBLAZER‐ALZ 2 (NCT04437511) is a multicenter, randomized, double-blind, placebo-controlled (PC) Phase 3 trial designed to assess the efficacy and safety of donanemab in participants with early symptomatic Alzheimer's disease. Lilly continues to study donanemab in multiple clinical trials, including TRAILBLAZER-ALZ 3, which is evaluating the safety and efficacy of donanemab in patients with preclinical Alzheimer's disease to determine if it reduces risk of progression to symptomatic Alzheimer's disease. TRAILBLAZER-ALZ 5 is a registration trial for early symptomatic Alzheimer's disease currently enrolling in China, Korea, Taiwan, and other geographies. The TRAILBLAZER-ALZ 6 study recently completed the 18-month final study endpoint. Data from the study showed that a modified titration dosing schedule reduced the risk of ARIA-E compared to the TRAILBLAZER-ALZ 2 dosing regimen. These findings supported the FDA approval of an update to the U.S. prescribing information for Kisunla. This data was also presented at AAIC. INDICATION AND SAFETY SUMMARY WITH WARNINGS Kisunla (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or "ARIA." This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal. ARIA is most commonly seen as temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the brain and infrequently, larger areas of bleeding in the brain can occur. Although most people do not have symptoms, some people have headaches, dizziness, nausea, difficulty walking, confusion, vision changes and seizures. Some people have a genetic risk factor (homozygous apolipoprotein E ε4 gene carriers) that may cause an increased risk for ARIA. Talk to your healthcare provider about testing to see if you have this risk factor. You may be at higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving Kisunla. Talk to your healthcare provider to see if you are on any medicines that increase this risk. Your healthcare provider will do magnetic resonance imaging (MRI) brain scans before and during your treatment with Kisunla to check you for ARIA. You should carry information that you are receiving Kisunla, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above. There are registries that collect information on treatments for Alzheimer's disease. Your healthcare provider can help you become enrolled in these registries. Warnings - Kisunla can cause serious allergic and infusion-related reactions. Do not receive Kisunla if you have serious allergic reactions to donanemab-azbt or any of the ingredients in Kisunla. Symptoms may include swelling of the face, lips, mouth, or eyelids, problems breathing, hives, chills, irritation of skin, nausea, vomiting, sweating, headache, or chest pain. You will be monitored for at least 30 minutes after you receive Kisunla for any reaction. Tell your healthcare provider right away if you have these symptoms or any reaction during or after a Kisunla infusion. Other common side effects Headache Tell your healthcare provider right away if you have any side effects. These are not all of the possible side effects of Kisunla. You can report side effects at 1-800-FDA-1088 or Before you receive Kisunla, tell your healthcare provider: About all medicines you take, including prescription and over-the-counter medicines, as well as vitamins and herbal supplements. Especially tell your healthcare provider if you have medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin). About all of your medical conditions including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. Kisunla has not been studied in people who were pregnant or breastfeeding. It is not known if Kisunla could harm your unborn or breastfeeding baby. How to receive KisunlaKisunla is a prescription medicine given through an intravenous (IV) infusion using a needle inserted into a vein in your arm. Kisunla is given once every 4 weeks. Each infusion will last about 30 minutes. Learn more For more information about Kisunla, call 1-800-LillyRx (1-800-545-5979) or go to This summary provides basic information about Kisunla. It does not include all information known about this medicine. Read the information given to you about Kisunla. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Kisunla. Your healthcare provider is the best person to help you decide if Kisunla is right for you. Please see full Prescribing Information including boxed warning for ARIA and Medication Guide for Kisunla. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram and LinkedIn. P-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Kisunla (donanemab-azbt) as a treatment for people with early symptomatic Alzheimer's disease, and regulatory approval and other milestones relating to Kisunla and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study findings to date, that Kisunla will receive additional regulatory approvals or that Kisunla will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. References Eli Lilly. A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2). identifier: NCT04437511. Updated May 4, 2025. Accessed September 30, 2024. Kisunla (donanemab-azbt). Prescribing Information. Lilly USA, LLC. Kisunla (donanemab-azbt). Medication Guide. Lilly USA, LLC. Refer to: Tammy McGuire; tmcguire@ 317-614-5132 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
a day ago
- Health
- Globe and Mail
Sleep Apnea Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Sleep Apnea Pipeline Insight, 2025' report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Sleep Apnea Treatment Landscape. Click here to read more @ Sleep Apnea Pipeline Outlook Key Takeaways from the Sleep Apnea Pipeline Report In July 2025, Mineralys Therapeutics Inc. announced a study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period. Participants must be 18 to 75 years old with moderate to severe OSA, hypertension and meet all applicable eligibility criteria. Participants who are medically prescribed and deemed compliant with positive airway pressure (PAP) therapy for greater than or equal to (>=) 4 hours per night (Continuous PAP [CPAP], or automatic PAP [autoPAP]) and for at least 3 months prior to the study enrollment are eligible for the study. In July 2025, Eli Lilly and Company announced a study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. DelveInsight's Sleep Apnea pipeline report depicts a robust space with 10+ active players working to develop 14+ pipeline therapies for Sleep Apnea treatment. The leading Sleep Apnea Companies such as Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Promising Sleep Apnea Pipeline Therapies such as Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Stay informed about the cutting-edge advancements in Sleep Apnea Treatments. Download for updates and be a part of the revolution in dermatology care @ Sleep Apnea Clinical Trials Assessment Sleep Apnea Emerging Drugs Profile AD109: Apnimed AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the hypoglossal motor nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse. It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines company's novel selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine). AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. AD109 has the potential to become a safe, effective, and convenient treatment for OSA, addressing some of the key limitations of current standard of care treatments that can be poorly tolerated (e.g., CPAP and oral devices) and/or invasive (e.g., surgery or implanted devices). Currently, the drug is in the Phase III stage of its development for the treatment of Obstructive Sleep Apnea. Dronabinol: RespireRx Phamaceuticals Dronabinol is a synthetic form of tetrahydrocannabinol (THC), the active compound in cannabis, primarily used to treat nausea, vomiting, and appetite loss. Research has shown potential for dronabinol in treating sleep apnea by stimulating the body's endocannabinoid receptors, which may help reduce apnea episodes and stabilize breathing during sleep. While not yet FDA-approved for sleep apnea, clinical studies suggest it could be beneficial in managing obstructive sleep apnea (OSA) symptoms. Currently, the drug is in the Phase II stage of its development for the treatment of Sleep Apnea. Gal 475: Neurim Pharmaceuticals GAL-475 is a novel therapeutic agent for the treatment of sleep apnea syndromes. In a series of in vitro and in vivo studies in various animal models it demonstrated improvements in sleep apnea indices with reductions in both the frequency and severity of events, without stimulating minute ventilation or disturbing sleep. Preclinical pharmacology studies with GAL-475 suggest that the compound acts predominantly as a peripheral chemoreception modulator, and indicate that the compound is effective in increasing respiratory drive to the upper airways and ameliorating obstructive apneas and their attendant sequelae in rodent models of obstructive apnea at relatively low plasma levels. The primary site of action for GAL-475 appears to be at the level of the carotid body, a peripheral polymodal chemosensory organ, located at the carotid bifurcation, responsible for sensing changes in partial pressures of O2, CO2 or pH, and activating the brainstem respiratory center to produce hyperventilation. Currently, the drug is in the Phase I stage of its development for the treatment of Sleep Apnea. The Sleep Apnea pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Sleep Apnea with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sleep Apnea Treatment. Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sleep Apnea market. Get a detailed analysis of the latest innovations in the Sleep Apnea pipeline. Explore DelveInsight's expert-driven report today! @ Sleep Apnea Unmet Needs Sleep Apnea Companies Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Sleep Apnea Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Sleep Apnea Treatment by visiting our website. Stay informed about how we're transforming the future of Dermatology @ Sleep Apnea Market Drivers and Barriers, and Future Perspectives Scope of the Sleep Apnea Pipeline Report Coverage- Global Sleep Apnea Companies- Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea Pipeline Therapies- Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Sleep Apnea Pipeline on our website @ Sleep Apnea Emerging Drugs and Companies Table of Contents Introduction Executive Summary Sleep Apnea: Overview Pipeline Therapeutics Therapeutic Assessment Sleep Apnea– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AD109: Apnimed Drug profiles in the detailed report….. Mid Stage Products (Phase II) Dronabinol: RespireRx Phamaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Gal 475: Neurim Pharmaceuticals Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Sleep Apnea Key Companies Sleep Apnea Key Products Sleep Apnea- Unmet Needs Sleep Apnea- Market Drivers and Barriers Sleep Apnea- Future Perspectives and Conclusion Sleep Apnea Analyst Views Sleep Apnea Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
a day ago
- Health
- Yahoo
LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro
A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications New York, July 29, 2025 (GLOBE NEWSWIRE) -- Disclaimer: The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Trademark Disclaimer: Mounjaro® is a registered trademark of Eli Lilly and Company. This article and the product discussed herein are not affiliated with, endorsed by, or approved by Eli Lilly. The mention of Mounjaro is for informational and comparative purposes only, to provide readers with contextual background regarding GLP-1 and GIP mechanisms. In response to the surge in interest around GLP-1-based medications like Mounjaro® and the rise in consumer searches for 'natural Mounjaro alternatives,' the team behind LipoVive has published a new ingredient-focused report. The editorial examines how botanical compounds and minerals may support similar hormonal pathways involved in appetite regulation, metabolic thermogenesis, and blood sugar balance — without requiring synthetic drugs or injections. to explore the full breakdown of these ingredients and how they compare to synthetic GLP-1 strategies. The announcement comes amid heightened public interest in hormone-based weight management strategies. GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) are two of the most researched hormones tied to satiety and insulin response. While prescription medications stimulate these receptors pharmacologically, many consumers are now exploring non-pharmaceutical routes that offer comparable metabolic support using ingredients derived from herbs, minerals, and antioxidant-rich extracts. A Science-Aligned Approach to Hormone-Supportive Weight Management Unlike traditional stimulant-based weight loss supplements, LipoVive is formulated to support the body's natural hormonal rhythm. Its six active ingredients — magnesium, zinc, chrysin, Tribulus terrestris, Chinese hawthorn, and saw palmetto — are selected to work synergistically across multiple metabolic touchpoints. The company's new report outlines how these ingredients may align with GLP-1 and GIP signaling goals, including support for: Improved insulin sensitivity Reduced appetite and cravings Enhanced thermogenesis and fat oxidation Regulation of core body temperature for metabolic activation Explore the Science Behind LipoVive's Natural Hormonal Support By framing the discussion through a science-forward lens, the report aims to inform consumers about viable, nature-based strategies that complement — rather than replace — mainstream options. Understanding GLP-1, GIP, and the Role of Hormonal Signals in Metabolism GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) are naturally occurring hormones that play a key role in how the body manages hunger, insulin response, and fat storage. These incretin hormones help regulate: Post-meal blood sugar levels Satiety signals to the brain Rate of fat oxidation Storage and utilization of energy Synthetic GLP-1 receptor agonists like Mounjaro® and Ozempic® mimic these hormones and are commonly prescribed to address obesity and type 2 diabetes. However, due to cost, access restrictions, and the potential for side effects such as nausea or muscle loss, consumers are increasingly searching for natural compounds that may support similar pathways without synthetic intervention. LipoVive was developed in response to this growing demand. Rather than flood the system with synthetic analogues, LipoVive is designed to help the body regulate its own hormonal activity — with ingredients selected to support core metabolic processes LipoVive's Natural Ingredients Compare to Synthetic GLP-1 Agonists Unlike prescription medications that require injections and work by overriding the body's natural hormonal rhythms, LipoVive takes a gentler approach — supporting the same metabolic goals through carefully selected nutrients and botanicals. The formula includes six active ingredients, each chosen for its potential role in appetite regulation, insulin sensitivity, and fat metabolism: Magnesium – Supports energy production, insulin signaling, and carbohydrate processing, all of which are targeted by GLP-1 medications. Zinc – Contributes to enzymatic function and hormone balance. It plays a role in appetite regulation and has been linked to improved fat oxidation. Tribulus Terrestris – Traditionally used for vitality, this adaptogen may support hormonal balance and physical energy levels, which can enhance the body's natural fat-burning capacity. Chrysin – A flavonoid studied for its antioxidant and hormone-modulating effects, chrysin may assist with reducing oxidative stress and maintaining lean body mass. Saw Palmetto Extract – Commonly used for endocrine support, saw palmetto may help maintain healthy androgen levels — relevant to fat storage and metabolism. Chinese Hawthorn (Crataegus pinnatifida) – Used in traditional medicine for digestion and circulation, this botanical may help improve lipid profiles and nutrient delivery. Together, these ingredients aim to support similar outcomes to synthetic drugs like Mounjaro — without injections, prescriptions, or synthetic Core Body Temperature Plays a Role in Fat Metabolism Recent research suggests that internal body temperature may play a critical role in metabolic efficiency. Individuals with consistently low core temperatures often experience slower metabolic rates, reduced fat-burning capacity, and stubborn weight retention — even when following strict diet and exercise routines. This concept ties into thermogenesis, the body's process of generating heat to burn energy. When thermogenesis is sluggish, fat oxidation slows. Conversely, mild increases in internal temperature can stimulate brown adipose tissue activity, helping the body convert stored fat into usable energy. LipoVive incorporates non-stimulant ingredients that may assist in gently raising internal temperature. Rather than using caffeine or harsh thermogenics, the formula leverages botanical extracts and minerals that support both warmth and metabolic balance — a dual approach for individuals who struggle with cold extremities, slow digestion, or weight plateaus. By supporting hormonal alignment and encouraging mild thermogenesis, LipoVive provides a unique angle on natural weight support — one that goes beyond the one-dimensional strategies of many over-the-counter fat Sets LipoVive Apart from Stimulant-Based Fat Burners Many popular fat-burning supplements rely on caffeine, diuretics, or artificial appetite suppressants to produce short-term effects. While these compounds can lead to temporary weight loss or water reduction, they often fail to address the underlying hormonal imbalances that make fat loss difficult — especially for adults over 35. LipoVive takes a different approach. Instead of artificial spikes in energy or metabolism, the formula focuses on restoring natural balance across multiple systems: Hormonal alignment through magnesium, zinc, and adaptogenic herbs Thermogenic support without jitters or crashes Improved digestion and circulation, which may help with nutrient delivery and fat metabolism This makes LipoVive appealing to individuals who are sensitive to stimulants, those experiencing hormonal changes related to age, or anyone seeking long-term support over quick fixes. Its formulation — including non-GMO ingredients, U.S.-based manufacturing, and third-party testing — reinforces its positioning as a wellness-forward solution for metabolic and GIP: Two Hormones at the Center of Today's Weight Loss Conversation Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are two of the most researched metabolic hormones in modern medicine. These naturally occurring compounds play crucial roles in regulating appetite, blood sugar, and fat storage — making them central targets in today's pharmaceutical weight loss solutions. Synthetic drugs like Mounjaro® function by artificially activating GLP-1 and GIP receptors. This stimulation reduces appetite, slows digestion, and improves glucose handling — leading to measurable weight loss. However, the cost, injection requirements, and potential side effects have led many to seek alternatives. LipoVive offers a different strategy: support the body's own GLP-1 and GIP signaling systems using nutrients and botanical compounds shown to influence these pathways naturally. Emerging research highlights that certain plant-based ingredients may: Encourage natural GLP-1 production Improve post-meal blood sugar control Enhance satiety signals without synthetic intervention LipoVive's formulation embraces these mechanisms while avoiding pharmaceutical dependence — offering consumers a gentle, hormone-aligned approach to weight Comparison: Natural vs. Synthetic Approaches to GLP-1 Support With synthetic GLP-1 receptor agonists dominating headlines — including injections like Mounjaro® and Wegovy® — consumers are increasingly curious about natural ways to support similar metabolic functions without pharmaceutical intervention. Below is a direct comparison between drug-based strategies and LipoVive's botanical pathway: Synthetic GLP-1 Drugs (e.g., Mounjaro®) Mechanism: Artificially mimic GLP-1 and GIP hormones Delivery: Typically injectable, requiring medical supervision Effects: Rapid appetite suppression and weight loss Limitations: High cost, potential digestive side effects, long-term dependency LipoVive Natural Support Mechanism: Encourages the body's own hormone balance via micronutrients and botanicals Delivery: Capsule form; taken orally once per day Effects: Gradual appetite control, metabolic support, thermogenesis Strengths: Caffeine-free, non-GMO, no injections, gentle on digestion LipoVive's six core ingredients include: Magnesium – Supports insulin sensitivity and metabolic enzyme function Zinc – Critical for hormone production and satiety signaling Tribulus Terrestris – Traditional vitality enhancer tied to fat metabolism Chrysin – Antioxidant flavonoid that may regulate hormonal feedback Saw Palmetto – Promotes endocrine balance Chinese Hawthorn – Aids digestion, circulation, and lipid regulation Together, these ingredients form a non-stimulant matrix that supports natural weight management through hormonal and thermogenic LipoVive May Be Safer for Long-Term Use Than Stimulant-Based Fat Burners One of the biggest challenges in the supplement industry is finding solutions that are both effective and sustainable. While many fat burners rely on stimulants like caffeine or yohimbine, LipoVive takes a different approach — prioritizing internal hormone balance over short-term energy spikes. This distinction is especially important for individuals who: Experience side effects from stimulants Struggle with appetite regulation and insulin sensitivity Are looking for a gentler, longer-term strategy that works with the body — not against it LipoVive's formula avoids the use of caffeine, diuretics, and harsh appetite suppressants. Instead, it includes ingredients known for: Gently raising core body temperature to support thermogenesis Encouraging satiety and metabolic balance via micronutrient pathways Supporting natural GLP-1 and GIP signals without disrupting endocrine rhythms By offering this kind of dual-action support — hormonal and thermogenic — LipoVive positions itself as a daily-use supplement that's both well-tolerated and scalable over Asked Questions About LipoVive and Natural GLP-1 Support As public awareness of GLP-1 hormone science grows, many consumers are turning to ingredient-based solutions like LipoVive. Below are answers to some of the most common questions related to the product and its function. What does LipoVive actually do?LipoVive supports the body's own GLP-1 and GIP pathways—two natural hormones involved in hunger regulation, fat metabolism, and insulin sensitivity. Its formula includes minerals, adaptogens, and thermogenic ingredients to help balance these systems. Is LipoVive a drug or medication?No. LipoVive is a dietary supplement and does not contain synthetic GLP-1 agonists. It is not a replacement for Mounjaro®, Ozempic®, or any prescription treatment, and is intended for general wellness support only. When can users expect results?Most individuals report improved appetite control, digestion, and energy within the first two weeks. Visible weight management benefits typically take 4–8 weeks when used consistently with lifestyle support. Are there side effects?LipoVive does not contain caffeine, synthetic stimulants, or common allergens. The majority of users tolerate it well. As with any supplement, users should consult a healthcare provider before beginning use, especially if they have a medical condition. How is LipoVive taken?One capsule per day with water, preferably in the morning. No cycling or loading phases are required. Where is LipoVive manufactured?It is produced in the United States in GMP-certified, FDA-registered facilities using non-GMO ingredients and third-party testing protocols. Is it available in stores?No. LipoVive is exclusively available through its official website, which helps ensure product authenticity and includes digital health bonuses. Digital Wellness Bonuses Included With Select LipoVive Packages To further support individuals exploring natural metabolic health strategies, the creators of LipoVive now include several digital bonus guides with qualifying orders. These educational resources are designed to complement the supplement's GLP-1-aligned formulation and offer practical tools for whole-body wellness. Bonus #1: Detox Gut Cleanse — 'Go Every Day' ProtocolA step-by-step guide designed to support digestive regularity and reduce bloating using natural herbs, hydration strategies, and fiber-rich foods. This protocol pairs well with LipoVive's hormonal focus for more complete metabolic alignment. Bonus #2: Fortifying Smoothies — Recipes for Circulation SupportThis collection of anti-inflammatory, antioxidant-rich smoothie recipes is designed to improve nutrient absorption and promote better blood flow—critical factors for metabolic efficiency and fat mobilization. Bonus #3: The Apple Trick — A Tonifying Tonic for Blood Sugar SupportA fruit-based recipe that supports insulin sensitivity and hydration. While not a treatment or cure, this blend aligns with LipoVive's approach to natural blood sugar balance. Bonus #4: The Secret Indian Cocktail — Adaptogenic Support for Mood and MotivationThis tonic draws on traditional Ayurvedic ingredients to help regulate stress-related eating, nighttime cravings, and emotional well-being. It supports overall motivation and resilience during lifestyle changes. These digital resources are delivered instantly after checkout with eligible multi-bottle LipoVive Thoughts on LipoVive's Natural Metabolic Support Strategy Rather than relying on a single 'hero ingredient,' LipoVive's formula reflects a synergistic blend of botanical and mineral-based compounds. By combining nutrients like magnesium, zinc, Tribulus terrestris, chrysin, saw palmetto, and Chinese hawthorn, the supplement is designed to align with GLP-1 and GIP-related metabolic pathways — without synthetic intervention or stimulants. This multi-pronged approach highlights a growing interest in natural hormonal balance, internal thermogenesis, and non-pharmaceutical appetite regulation — positioning LipoVive as part of a larger conversation around lifestyle-friendly metabolic support and Important Notices The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Mounjaro® is a registered trademark of Eli Lilly and Company. This article and the product discussed herein are not affiliated with, endorsed by, or approved by Eli Lilly. The mention of Mounjaro is for informational and comparative purposes only, to provide readers with contextual background regarding GLP-1 and GIP mechanisms. Statements in this article have not been evaluated by the Food and Drug Administration. Products referenced are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always follow label directions and consult with a licensed professional before using any dietary supplement. To learn more about LipoVive or to explore its full ingredient profile, visit the official site here: CONTACT: Email: support@ Phone: (970) 406-7582Sign in to access your portfolio
Business Upturn
a day ago
- Health
- Business Upturn
LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro
New York, July 29, 2025 (GLOBE NEWSWIRE) — Disclaimer: The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Trademark Disclaimer: Mounjaro® is a registered trademark of Eli Lilly and Company. This article and the product discussed herein are not affiliated with, endorsed by, or approved by Eli Lilly. The mention of Mounjaro is for informational and comparative purposes only, to provide readers with contextual background regarding GLP-1 and GIP mechanisms. In response to the surge in interest around GLP-1-based medications like Mounjaro® and the rise in consumer searches for 'natural Mounjaro alternatives,' the team behind LipoVive has published a new ingredient-focused report. The editorial examines how botanical compounds and minerals may support similar hormonal pathways involved in appetite regulation, metabolic thermogenesis, and blood sugar balance — without requiring synthetic drugs or injections. Visit the Official LipoVive Site to explore the full breakdown of these ingredients and how they compare to synthetic GLP-1 strategies. The announcement comes amid heightened public interest in hormone-based weight management strategies. GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) are two of the most researched hormones tied to satiety and insulin response. While prescription medications stimulate these receptors pharmacologically, many consumers are now exploring non-pharmaceutical routes that offer comparable metabolic support using ingredients derived from herbs, minerals, and antioxidant-rich extracts. A Science-Aligned Approach to Hormone-Supportive Weight Management Unlike traditional stimulant-based weight loss supplements, LipoVive is formulated to support the body's natural hormonal rhythm. Its six active ingredients — magnesium, zinc, chrysin, Tribulus terrestris, Chinese hawthorn, and saw palmetto — are selected to work synergistically across multiple metabolic touchpoints. The company's new report outlines how these ingredients may align with GLP-1 and GIP signaling goals, including support for: Improved insulin sensitivity Reduced appetite and cravings Enhanced thermogenesis and fat oxidation Regulation of core body temperature for metabolic activation Explore the Science Behind LipoVive's Natural Hormonal Support By framing the discussion through a science-forward lens, the report aims to inform consumers about viable, nature-based strategies that complement — rather than replace — mainstream options. Understanding GLP-1, GIP, and the Role of Hormonal Signals in Metabolism GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitory polypeptide) are naturally occurring hormones that play a key role in how the body manages hunger, insulin response, and fat storage. These incretin hormones help regulate: Post-meal blood sugar levels Satiety signals to the brain Rate of fat oxidation Storage and utilization of energy Synthetic GLP-1 receptor agonists like Mounjaro® and Ozempic® mimic these hormones and are commonly prescribed to address obesity and type 2 diabetes. However, due to cost, access restrictions, and the potential for side effects such as nausea or muscle loss, consumers are increasingly searching for natural compounds that may support similar pathways without synthetic intervention. LipoVive was developed in response to this growing demand. Rather than flood the system with synthetic analogues, LipoVive is designed to help the body regulate its own hormonal activity — with ingredients selected to support core metabolic processes naturally. Learn More About the Natural Hormone Support in LipoVive How LipoVive's Natural Ingredients Compare to Synthetic GLP-1 Agonists Unlike prescription medications that require injections and work by overriding the body's natural hormonal rhythms, LipoVive takes a gentler approach — supporting the same metabolic goals through carefully selected nutrients and botanicals. The formula includes six active ingredients, each chosen for its potential role in appetite regulation, insulin sensitivity, and fat metabolism: Magnesium – Supports energy production, insulin signaling, and carbohydrate processing, all of which are targeted by GLP-1 medications. Zinc – Contributes to enzymatic function and hormone balance. It plays a role in appetite regulation and has been linked to improved fat oxidation. Tribulus Terrestris – Traditionally used for vitality, this adaptogen may support hormonal balance and physical energy levels, which can enhance the body's natural fat-burning capacity. Chrysin – A flavonoid studied for its antioxidant and hormone-modulating effects, chrysin may assist with reducing oxidative stress and maintaining lean body mass. Saw Palmetto Extract – Commonly used for endocrine support, saw palmetto may help maintain healthy androgen levels — relevant to fat storage and metabolism. Chinese Hawthorn (Crataegus pinnatifida) – Used in traditional medicine for digestion and circulation, this botanical may help improve lipid profiles and nutrient delivery. Together, these ingredients aim to support similar outcomes to synthetic drugs like Mounjaro — without injections, prescriptions, or synthetic compounds. View the Full Ingredient Breakdown on the Official LipoVive Site Why Core Body Temperature Plays a Role in Fat Metabolism Recent research suggests that internal body temperature may play a critical role in metabolic efficiency. Individuals with consistently low core temperatures often experience slower metabolic rates, reduced fat-burning capacity, and stubborn weight retention — even when following strict diet and exercise routines. This concept ties into thermogenesis, the body's process of generating heat to burn energy. When thermogenesis is sluggish, fat oxidation slows. Conversely, mild increases in internal temperature can stimulate brown adipose tissue activity, helping the body convert stored fat into usable energy. LipoVive incorporates non-stimulant ingredients that may assist in gently raising internal temperature. Rather than using caffeine or harsh thermogenics, the formula leverages botanical extracts and minerals that support both warmth and metabolic balance — a dual approach for individuals who struggle with cold extremities, slow digestion, or weight plateaus. By supporting hormonal alignment and encouraging mild thermogenesis, LipoVive provides a unique angle on natural weight support — one that goes beyond the one-dimensional strategies of many over-the-counter fat burners. Explore How LipoVive Supports Fat Metabolism Without Stimulants What Sets LipoVive Apart from Stimulant-Based Fat Burners Many popular fat-burning supplements rely on caffeine, diuretics, or artificial appetite suppressants to produce short-term effects. While these compounds can lead to temporary weight loss or water reduction, they often fail to address the underlying hormonal imbalances that make fat loss difficult — especially for adults over 35. LipoVive takes a different approach. Instead of artificial spikes in energy or metabolism, the formula focuses on restoring natural balance across multiple systems: Hormonal alignment through magnesium, zinc, and adaptogenic herbs through magnesium, zinc, and adaptogenic herbs Thermogenic support without jitters or crashes without jitters or crashes Improved digestion and circulation, which may help with nutrient delivery and fat metabolism This makes LipoVive appealing to individuals who are sensitive to stimulants, those experiencing hormonal changes related to age, or anyone seeking long-term support over quick fixes. Its formulation — including non-GMO ingredients, U.S.-based manufacturing, and third-party testing — reinforces its positioning as a wellness-forward solution for metabolic health. Visit the Official LipoVive Site for Full Product Details GLP-1 and GIP: Two Hormones at the Center of Today's Weight Loss Conversation Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are two of the most researched metabolic hormones in modern medicine. These naturally occurring compounds play crucial roles in regulating appetite, blood sugar, and fat storage — making them central targets in today's pharmaceutical weight loss solutions. Synthetic drugs like Mounjaro® function by artificially activating GLP-1 and GIP receptors. This stimulation reduces appetite, slows digestion, and improves glucose handling — leading to measurable weight loss. However, the cost, injection requirements, and potential side effects have led many to seek alternatives. LipoVive offers a different strategy: support the body's own GLP-1 and GIP signaling systems using nutrients and botanical compounds shown to influence these pathways naturally. Emerging research highlights that certain plant-based ingredients may: Encourage natural GLP-1 production Improve post-meal blood sugar control Enhance satiety signals without synthetic intervention LipoVive's formulation embraces these mechanisms while avoiding pharmaceutical dependence — offering consumers a gentle, hormone-aligned approach to weight management. Explore LipoVive's Natural GLP-1 Strategy Ingredient Comparison: Natural vs. Synthetic Approaches to GLP-1 Support With synthetic GLP-1 receptor agonists dominating headlines — including injections like Mounjaro® and Wegovy® — consumers are increasingly curious about natural ways to support similar metabolic functions without pharmaceutical intervention. Below is a direct comparison between drug-based strategies and LipoVive's botanical pathway: Synthetic GLP-1 Drugs (e.g., Mounjaro®) Mechanism: Artificially mimic GLP-1 and GIP hormones Artificially mimic GLP-1 and GIP hormones Delivery: Typically injectable, requiring medical supervision Typically injectable, requiring medical supervision Effects: Rapid appetite suppression and weight loss Rapid appetite suppression and weight loss Limitations: High cost, potential digestive side effects, long-term dependency LipoVive Natural Support Mechanism: Encourages the body's own hormone balance via micronutrients and botanicals Encourages the body's own hormone balance via micronutrients and botanicals Delivery: Capsule form; taken orally once per day Capsule form; taken orally once per day Effects: Gradual appetite control, metabolic support, thermogenesis Gradual appetite control, metabolic support, thermogenesis Strengths: Caffeine-free, non-GMO, no injections, gentle on digestion LipoVive's six core ingredients include: Magnesium – Supports insulin sensitivity and metabolic enzyme function – Supports insulin sensitivity and metabolic enzyme function Zinc – Critical for hormone production and satiety signaling – Critical for hormone production and satiety signaling Tribulus Terrestris – Traditional vitality enhancer tied to fat metabolism – Traditional vitality enhancer tied to fat metabolism Chrysin – Antioxidant flavonoid that may regulate hormonal feedback – Antioxidant flavonoid that may regulate hormonal feedback Saw Palmetto – Promotes endocrine balance – Promotes endocrine balance Chinese Hawthorn – Aids digestion, circulation, and lipid regulation Together, these ingredients form a non-stimulant matrix that supports natural weight management through hormonal and thermogenic alignment. Learn More About LipoVive's Full Ingredient Profile Why LipoVive May Be Safer for Long-Term Use Than Stimulant-Based Fat Burners One of the biggest challenges in the supplement industry is finding solutions that are both effective and sustainable. While many fat burners rely on stimulants like caffeine or yohimbine, LipoVive takes a different approach — prioritizing internal hormone balance over short-term energy spikes. This distinction is especially important for individuals who: Experience side effects from stimulants Struggle with appetite regulation and insulin sensitivity Are looking for a gentler, longer-term strategy that works with the body — not against it LipoVive's formula avoids the use of caffeine, diuretics, and harsh appetite suppressants. Instead, it includes ingredients known for: Gently raising core body temperature to support thermogenesis Encouraging satiety and metabolic balance via micronutrient pathways Supporting natural GLP-1 and GIP signals without disrupting endocrine rhythms By offering this kind of dual-action support — hormonal and thermogenic — LipoVive positions itself as a daily-use supplement that's both well-tolerated and scalable over time. Discover Why LipoVive Is Stimulant-Free Frequently Asked Questions About LipoVive and Natural GLP-1 Support As public awareness of GLP-1 hormone science grows, many consumers are turning to ingredient-based solutions like LipoVive. Below are answers to some of the most common questions related to the product and its function. What does LipoVive actually do? LipoVive supports the body's own GLP-1 and GIP pathways—two natural hormones involved in hunger regulation, fat metabolism, and insulin sensitivity. Its formula includes minerals, adaptogens, and thermogenic ingredients to help balance these systems. Is LipoVive a drug or medication? No. LipoVive is a dietary supplement and does not contain synthetic GLP-1 agonists. It is not a replacement for Mounjaro®, Ozempic®, or any prescription treatment, and is intended for general wellness support only. When can users expect results? Most individuals report improved appetite control, digestion, and energy within the first two weeks. Visible weight management benefits typically take 4–8 weeks when used consistently with lifestyle support. Are there side effects? LipoVive does not contain caffeine, synthetic stimulants, or common allergens. The majority of users tolerate it well. As with any supplement, users should consult a healthcare provider before beginning use, especially if they have a medical condition. How is LipoVive taken? One capsule per day with water, preferably in the morning. No cycling or loading phases are required. Where is LipoVive manufactured? It is produced in the United States in GMP-certified, FDA-registered facilities using non-GMO ingredients and third-party testing protocols. Is it available in stores? No. LipoVive is exclusively available through its official website, which helps ensure product authenticity and includes digital health bonuses. Digital Wellness Bonuses Included With Select LipoVive Packages To further support individuals exploring natural metabolic health strategies, the creators of LipoVive now include several digital bonus guides with qualifying orders. These educational resources are designed to complement the supplement's GLP-1-aligned formulation and offer practical tools for whole-body wellness. Bonus #1: Detox Gut Cleanse — 'Go Every Day' Protocol A step-by-step guide designed to support digestive regularity and reduce bloating using natural herbs, hydration strategies, and fiber-rich foods. This protocol pairs well with LipoVive's hormonal focus for more complete metabolic alignment. Bonus #2: Fortifying Smoothies — Recipes for Circulation Support This collection of anti-inflammatory, antioxidant-rich smoothie recipes is designed to improve nutrient absorption and promote better blood flow—critical factors for metabolic efficiency and fat mobilization. Bonus #3: The Apple Trick — A Tonifying Tonic for Blood Sugar Support A fruit-based recipe that supports insulin sensitivity and hydration. While not a treatment or cure, this blend aligns with LipoVive's approach to natural blood sugar balance. Bonus #4: The Secret Indian Cocktail — Adaptogenic Support for Mood and Motivation This tonic draws on traditional Ayurvedic ingredients to help regulate stress-related eating, nighttime cravings, and emotional well-being. It supports overall motivation and resilience during lifestyle changes. These digital resources are delivered instantly after checkout with eligible multi-bottle LipoVive packages. Click Here to Access the Full Bonus Package Final Thoughts on LipoVive's Natural Metabolic Support Strategy Rather than relying on a single 'hero ingredient,' LipoVive's formula reflects a synergistic blend of botanical and mineral-based compounds. By combining nutrients like magnesium, zinc, Tribulus terrestris, chrysin, saw palmetto, and Chinese hawthorn, the supplement is designed to align with GLP-1 and GIP-related metabolic pathways — without synthetic intervention or stimulants. This multi-pronged approach highlights a growing interest in natural hormonal balance, internal thermogenesis, and non-pharmaceutical appetite regulation — positioning LipoVive as part of a larger conversation around lifestyle-friendly metabolic support options. Visit the Official LipoVive Site to Learn More Disclaimers and Important Notices The information provided in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider before beginning any new supplement or wellness routine. Mounjaro® is a registered trademark of Eli Lilly and Company. This article and the product discussed herein are not affiliated with, endorsed by, or approved by Eli Lilly. The mention of Mounjaro is for informational and comparative purposes only, to provide readers with contextual background regarding GLP-1 and GIP mechanisms. Statements in this article have not been evaluated by the Food and Drug Administration. Products referenced are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always follow label directions and consult with a licensed professional before using any dietary supplement. To learn more about LipoVive or to explore its full ingredient profile, visit the official site here: Visit the Official LipoVive Site Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
23-07-2025
- Health
- Business Upturn
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer's associated amyloid pathology. The minimally invasive, blood-based test can serve as a rule out for Alzheimer's pathology, reducing the need for confirmatory testing with a negative result. Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer's disease. The test, which has been developed in collaboration with Eli Lilly and Company, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline. This could avoid the need for further confirmatory investigation for patients testing negative. 'The burden of Alzheimer's disease on society and healthcare systems is increasing as the world's population ages,' said Matt Sause, CEO of Roche Diagnostics. 'With Elecsys pTau181, doctors can give patients and their caregivers the clarity they need when establishing the cause of cognitive decline. By enabling an earlier and less invasive diagnosis, this test has the potential to improve patient outcomes and decrease costs for healthcare systems worldwide.' Barriers to early and accurate diagnosis of Alzheimer's disease exist across the world. Up to 75% of people living with symptoms are not diagnosed, and those who have received a diagnosis waited nearly three years on average after symptom onset.1 The identification of amyloid pathology is critical for Alzheimer's diagnosis and treatment. Current methods to confirm amyloid pathology – including positron emission tomography (PET) and cerebrospinal fluid (CSF) assessment – can be expensive, difficult to access and invasive. With a negative Elecsys pTau181 blood test, people can avoid further unnecessary investigations for Alzheimer's using CSF or PET and can identify the care pathway that is right for them. Clinical study results support that the test can be implemented effectively across care settings, including primary care, where most patients first seek help for cognitive concerns. Those with positive results are then able to undergo further testing, supporting earlier identification of Alzheimer's pathology. This is key to accessing new treatments that are most effective when used early in the disease progression, enabling patients to make informed decisions about their future care. Clinical data support the Elecsys pTau181 test for varying signs of cognitive decline The CE Mark for the Elecsys pTau181 blood test was based on data from a prospective, multicentre study, which included 787 patients across the US, Europe and Australia. The study showed the test was able to rule out Alzheimer's disease with a high negative predictive value (NPV) of 93.8% based on a 22.5% prevalence of amyloid positivity according to positron emission tomography (PET) scans, with 83.6% sensitivity. The rule out performance of the test was only minimally impacted by the patients' age, gender, body mass index or impaired kidney function. This global, prospectively-collected, diagnostic registrational clinical study was the first of its kind in the industry to investigate the test's clinical performance in a diverse patient population, aged 55-80 years old that reflects as closely as possible the patients who could benefit from the test. It involved a subset of patients from a wider study looking at a highly diverse set of patients with broad inclusion criteria, to ensure the test could be used effectively across different geographies and ethnicities. Elecsys pTau217 blood test Roche is also developing the Elecsys pTau217 blood test, an in-vitro diagnostic immunoassay for the quantitative determination of the protein Phospho-Tau (217P) in human plasma for use as an aid in identifying amyloid pathology. Recent data presented on Elecsys pTau217 showed that it was able to accurately detect amyloid pathology and was more stable than a pTau217/Aβ42 ratio in blood and plasma samples at room and refrigerator temperatures. Together with the high throughput and full automation of the assay, these data support the potential of Elecsys pTau217 as an accurate standalone test that could be scaled up for broad implementation in routine clinical practice worldwide across Roche's unmatched installed base. About Roche in Alzheimer's With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital, blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit . All trademarks used or mentioned in this release are protected by law. References [1] Alzheimer's Disease International. World Alzheimer Report 2022 [Internet; cited April 2025]. Available from: . Last accessed: April 2025 Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Investor Relations North America Loren KalmPhone: +1 650 225 3217 e-mail: [email protected] Attachment Media Investor Release Elecsys pTau181 CE Mark English Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
